NOV 17, 202661 MINS READ
Croscarmellose sodium is the sodium salt of a cross-linked, partially O-carboxymethylated cellulose, characterized by its three-dimensional polymeric network that imparts exceptional water uptake and swelling capacity 5. The cross-linking density and degree of substitution (typically 0.6–0.9 carboxymethyl groups per anhydroglucose unit) govern its disintegration kinetics and mechanical properties in compressed systems. Unlike linear cellulose derivatives, the cross-linked architecture prevents dissolution while enabling rapid hydration and volumetric expansion—up to 4–8 times its dry volume—creating disruptive forces within the tablet matrix 10.
In dry granulation processes, croscarmellose sodium functions through a dual mechanism: capillary wicking draws aqueous media into the granule structure, while subsequent swelling pressure (estimated at 10–50 kPa depending on concentration and particle size) fractures inter-particulate bonds formed during compaction 12. This mechanism is particularly effective when croscarmellose sodium is incorporated intragranularly (within the compacted slugs or ribbons) at 1–6% w/w, as the disintegrant becomes intimately distributed throughout the granule microstructure 1,5. The superdisintegrant's performance is superior to conventional disintegrants such as cornstarch or even other superdisintegrants like crospovidone and sodium starch glycolate, which failed to provide equivalent rapid disintegration in comparative dry granulation trials 5,12.
The particle size distribution of croscarmellose sodium also influences its efficacy: finer grades (D50 < 50 μm) provide faster wetting kinetics, while coarser grades (D50 > 100 μm) may enhance flowability during granulation and compression. Commercial grades such as Ac-Di-Sol (Type A) and CLD-2 (Type B) exhibit slightly different swelling rates and compressibility profiles, with Type A generally preferred for direct compression and dry granulation due to its superior flow properties and lower moisture sensitivity 1,5.
A critical formulation strategy in dry granulation involves the strategic partitioning of croscarmellose sodium between intragranular (within the compacted granules) and extragranular (added post-granulation) phases. Research demonstrates that optimal disintegration and dissolution performance is achieved when croscarmellose sodium is present in both phases, with the total concentration ranging from 1% to 15% w/w depending on API properties and target dissolution profile 4,10.
Intragranular croscarmellose sodium (typically 1–8% w/w of the granulation blend) is dry-mixed with the API and other excipients prior to roller compaction or slugging 1,5. This approach ensures uniform distribution throughout the granule core, enabling rapid disintegration from within once the dosage form contacts aqueous media. For high-dose formulations (e.g., ibuprofen tablets containing 85–99% API), intragranular croscarmellose sodium at 1–6% w/w combined with 0.4–1% colloidal silicon dioxide (as a glidant and moisture scavenger) and trace magnesium stearate (<0.3%) yielded granules with excellent flowability (Carr index <20) and compressibility 1. The dry mixing step must achieve "essentially uniform consistency" to prevent localized disintegrant-rich or disintegrant-poor regions that could compromise disintegration uniformity 5.
Extragranular croscarmellose sodium (added after milling the compacted slugs/ribbons, typically 2–10% w/w of the final blend) provides a secondary disintegration mechanism by creating preferential pathways for water ingress at the tablet surface and inter-granular spaces 4,10. In a sitagliptin hydrochloride monohydrate formulation prepared by wet granulation (but applicable principles for dry systems), the ratio of intragranular to extragranular croscarmellose sodium was optimized at 1:2.5, with total croscarmellose sodium at approximately 6–8% w/w, achieving disintegration times of 2–3 minutes and >85% dissolution within 15 minutes 4. For dry granulation systems, a similar or slightly higher total concentration (up to 15%) may be required due to the absence of binder-induced porosity.
The synergistic effect of dual-phase croscarmellose sodium is particularly evident in formulations containing hygroscopic or poorly compressible APIs. For instance, in a composition containing a water-labile compound with waxy consistency, intragranular croscarmellose sodium (5–7% w/w) combined with crospovidone and microcrystalline cellulose, followed by extragranular addition of croscarmellose sodium (3–5% w/w), enabled successful dry granulation and tablet compression with acceptable friability (<0.5%) and rapid disintegration 6,7,8.
The efficacy of croscarmellose sodium in dry granulation is highly dependent on process parameters during roller compaction or slugging, as these determine granule density, porosity, and disintegrant accessibility to aqueous media.
Roller compaction pressures typically range from 20 to 100 MPa (2–10 tons/cm² linear force), with optimal pressures for croscarmellose sodium-containing blends generally at 30–50 MPa 9,11. At 35 MPa, drug-loaded ordered mesoporous silica blends containing croscarmellose sodium (composition details in 11) achieved Carr indices ≤25 after milling, indicating good to excellent flowability. Excessive compaction pressure (>60 MPa) can over-densify granules, reducing porosity and hindering water penetration to the intragranular croscarmellose sodium, thereby prolonging disintegration times. Conversely, insufficient pressure (<25 MPa) yields friable granules with poor tablet-forming properties.
The ribbon or slug density should target 1.0–1.3 g/cm³ for most formulations; croscarmellose sodium's low bulk density (0.5–0.7 g/cm³) and high compressibility help achieve this range without requiring excessive force 1,5. Post-compaction, the ribbons/slugs are milled through oscillating granulators or hammer mills and screened (typically through 16–30 mesh, 600–1200 μm) to produce uniform granules 1,5.
Granule size distribution critically affects both flowability and disintegration. A target D50 of 200–500 μm with <10% fines (<100 μm) and <5% oversize (>1000 μm) is recommended 9,11. Croscarmellose sodium's fibrous morphology can cause some granules to be elongated; vibratory sieving or air classification may be necessary to remove these and ensure uniform flow into the tablet press 1. In one study, granules containing 30% drug-loaded mesoporous silica, microcrystalline cellulose, and croscarmellose sodium exhibited Carr indices of 15–22 and Hausner ratios of 1.18–1.28 after slugging at 35 MPa and sieving through 900 μm, indicating excellent flow 11.
Croscarmellose sodium is hygroscopic (equilibrium moisture content 5–8% at 50% RH, 25°C), and moisture uptake during processing can prematurely activate its swelling mechanism, leading to poor granule flow and compaction issues 5,10. Dry granulation processes should maintain relative humidity <40% and temperature 20–25°C. If the API is moisture-sensitive, the intragranular blend may include 0.5–1% colloidal silicon dioxide (e.g., Aerosil 200) as a desiccant and glidant 1,6. Post-granulation, the material should be stored in moisture-barrier containers and processed promptly to prevent caking.
Magnesium stearate is the most common lubricant, typically added extragranularly at 0.25–1.0% w/w 1,4,5. Over-lubrication (>1% or prolonged blending >5 minutes) can coat croscarmellose sodium particles, reducing their wetting rate and impairing disintegration. Sodium stearyl fumarate (0.5–1.5%) is an alternative that provides lubrication with less hydrophobicity, and has been successfully used in croscarmellose sodium formulations 4,7. The lubricant should be added last and blended for only 2–3 minutes in a low-shear blender (e.g., V-blender or bin blender) to minimize coating effects.
Croscarmellose sodium's superiority in dry granulation has been demonstrated in head-to-head comparisons with other superdisintegrants. In ibuprofen dry granulation trials, crospovidone (cross-linked polyvinylpyrrolidone, Polyplasdone XL-10) and sodium starch glycolate were evaluated at equivalent concentrations (3–5% w/w) 5,12. Crospovidone failed to provide adequate disintegration, likely due to its lower swelling capacity (2–4× vs. 4–8× for croscarmellose sodium) and tendency to form a gel layer that retards further water ingress 5. Sodium starch glycolate developed a "ropy consistency" during slurry preparation (in wet granulation context) and exhibited inconsistent performance in dry systems, possibly due to its sensitivity to compaction pressure 12.
In contrast, croscarmellose sodium at 1–6% w/w in dry granulation consistently achieved disintegration times of 2–5 minutes and >80% dissolution within 15 minutes for poorly soluble APIs such as ibuprofen (log P ~3.5) and tadalafil (log P ~1.8) 1,3,13. For tadalafil, co-granulation with croscarmellose sodium at a 5:1 weight ratio (croscarmellose:API) via dry granulation significantly enhanced dissolution compared to formulations where croscarmellose sodium was simply dry-blended at conventional levels (0.5–5%) without pre-granulation 3,13. This suggests that intimate contact between API and disintegrant particles, achieved through compaction and milling, is critical for optimal performance.
Croscarmellose sodium has been extensively utilized in high-dose ibuprofen tablets (800–1200 mg per tablet) manufactured by dry granulation 1,5. A representative formulation contains 85–99% ibuprofen, 1–6% croscarmellose sodium (Type A or B), 0.4–1% colloidal silicon dioxide, and 0.2–0.3% magnesium stearate, all dry-mixed and roller-compacted at 30–40 MPa, then milled and compressed into tablets 1. These tablets exhibit bioavailability equivalent to lower-dose (200–400 mg) wet-granulated formulations, with Cmax and AUC within 90–110% of reference products, while offering improved patient compliance due to reduced pill burden 1,5. The high bulk density of the resulting granules (0.6–0.8 g/cm³) enables tablet weights of 1.0–1.5 g to be compressed into standard 18–22 mm diameter tooling, which is commercially viable 1.
Tadalafil, a BCS Class II drug with aqueous solubility <0.1 mg/mL, benefits significantly from co-granulation with croscarmellose sodium 3,13. A dry granulation process involves blending tadalafil (micronized, D90 <40 μm, though the invention demonstrates this is not strictly necessary) with croscarmellose sodium at a 1:5 to 1:10 drug:disintegrant ratio, compacting at 25–35 MPa, milling, and blending with extragranular microcrystalline cellulose and additional croscarmellose sodium to achieve a final tadalafil concentration of 2–10% w/w 3,13. This approach yields tablets with >70% dissolution at 30 minutes (pH 6.8, USP Apparatus II, 75 rpm), compared to <40% for non-co-granulated controls, attributed to the disintegrant's role in preventing API particle agglomeration and enhancing effective surface area upon disintegration 3,13.
For moisture-labile APIs such as amonavir or compounds with waxy consistency, dry granulation with croscarmellose sodium offers a solvent-free processing route 2,6,7,8. A typical formulation includes the API (40–60% w/w), croscarmellose sodium (5–10% intragranular, 3–5% extragranular), microcrystalline cellulose (20–30%), crospovidone (2–5%), and hydroxypropyl methylcellulose (1–3% as a dry binder) 6,7. The blend is compacted at 30–45 MPa, milled, and tableted with minimal exposure to humidity (<30% RH). Analytical methods such as HPLC-CAD (charged aerosol detection) have been developed to quantify croscarmellose sodium content in such formulations, ensuring consistency and enabling quality-by-design approaches 2. Recovery rates of 95–105% and RSD <3% demonstrate the method's precision, critical for regulatory submissions 2.
Sitagliptin hydrochloride monohydrate, a DPP-4 inhibitor, has been formulated using a modified wet granulation process that incorporates principles applicable to dry granulation: dual-phase croscarmellose sodium (intragranular and extragranular) combined with dibasic calcium phosphate in both phases 4. Although this example uses wet granulation, the strategic distribution of croscarmellose sodium (total 6–8% w/w, 1:2 intragranular:extragranular ratio) and the absence of traditional binders (water alone as granulating fluid) closely parallels
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| THE UPJOHN COMPANY | High-dose analgesic tablets for pain management requiring reduced pill burden, manufactured via roller compaction at 30-40 MPa without wet granulation, suitable for moisture-sensitive API processing. | High-Dose Ibuprofen Tablets (800-1200mg) | Dry granulation with 1-15% croscarmellose sodium achieves 85-99% ibuprofen content, rapid disintegration (2-5 minutes), and bioavailability equivalent to lower-dose formulations while maintaining high bulk density (0.6-0.8 g/cm³) and excellent compaction properties. |
| SYNTHON BV | Phosphodiesterase-5 inhibitor formulations for erectile dysfunction treatment, particularly for poorly water-soluble APIs (solubility <0.1 mg/mL) requiring enhanced dissolution profiles in immediate-release oral dosage forms. | Tadalafil Immediate Release Tablets | Co-granulation of tadalafil with croscarmellose sodium at 1:5 to 1:10 ratio via dry granulation at 25-35 MPa achieves >70% dissolution at 30 minutes compared to <40% for non-co-granulated controls, enhancing bioavailability of poorly soluble BCS Class II drug without requiring micronization. |
| SANTA FARMA İLAÇ SANAYİ A.Ş. | DPP-4 inhibitor tablets for type 2 diabetes management requiring rapid onset of action, manufactured with optimized wet/dry granulation hybrid approach ensuring consistent disintegration and dissolution performance. | Sitagliptin HCl Monohydrate Tablets | Dual-phase croscarmellose sodium distribution (intragranular:extragranular ratio 1:2.5, total 6-8% w/w) combined with dibasic calcium phosphate achieves disintegration time of 2-3 minutes, friability of 0.15%, and >85% dissolution within 15 minutes. |
| FORMAC PHARMACEUTICALS N.V. | Oral solid dosage forms for poorly soluble drugs requiring enhanced dissolution and bioavailability, utilizing mesoporous silica drug delivery systems in tablets manufactured by slugging and roller compaction processes. | Drug-Loaded Mesoporous Silica Tablets | Dry granulation of drug-loaded ordered mesoporous silica (30% drug loading) with croscarmellose sodium at 35 MPa compaction pressure yields granules with Carr index ≤25, Hausner ratio 1.18-1.28, and excellent flowability for poorly compressible APIs. |
| F.HOFFMANN-LA ROCHE AG | Antiviral and moisture-sensitive pharmaceutical compounds requiring solvent-free processing under controlled humidity (<30% RH), manufactured via dry granulation at 30-45 MPa to prevent API degradation during tablet production. | Moisture-Sensitive API Tablets | Dry granulation formulation with 5-10% intragranular and 3-5% extragranular croscarmellose sodium combined with crospovidone, microcrystalline cellulose, and HPMC enables processing of water-labile compounds with waxy consistency while maintaining tablet friability <0.5% and rapid disintegration. |